Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGB-19 versus reference tocilizumab equivalence study in healthy adult male volunteers
jRCT2031230029Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of HS628 and tocilizumab (2 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoints: Maximum serum drug concentration (Cmax) and AUC from 0 hours to infinity (AUCinf). Started Apr 2023; status: completed.
02
Drugs
HS628tocilizumab
Beyond the preview
Go deeper on jRCT2031230029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230029.